RT @HarveyHippoLab: Pleased to share our review in @NatRevDrugDisc. 20+ years after the Hippo pathway was discovered in Drosophila, the fir….

Our July issue is live! Read about neutrophil-targeting drugs, tumour-agnostic kinase inhibitors, computational drug repurposing, antifibrotic therapies and more here

For readers interested in novel therapeutic targets to combat Gram-negative bacterial infections, here's a comprehensive review

Our latest research highlight covers a paper in Science Translational Medicine on a prodrug based on a host defence peptide that is activated at sites of infection and shows potent antimicrobial activity in mouse models of Gram-negative bacterial infection

For readers interested in secondary pharmacology screening of small-molecule drug candidates and its impact on drug safety, here's a comprehensive discussion of the state of the art .

Two correspondence articles in the June issue discuss the inclusion of enzymes in secondary pharmacology screening panels to reduce the risks of off-target toxicities emerging for investigational drugs .

RT @diegoadiazg: 🧬 The gut microbiome shapes immune responses and may boost immunotherapy in cancer. New strategies, like FMT, probiotics,….

For readers interested in anticancer drugs, this review in the June issue discusses progress in targeting MYC, a key oncogene that was once viewed as undruggable, but is now being targeted by drugs in clinical trials

Targeting the Hippo pathway in cancer This new Review discusses emerging Hippo pathway-targeted therapies for cancer, particularly those that target TEAD DNA binding proteins and their interaction with the YAP/TAZ transcription co-activators

Metabolites as agents and targets for cancer immunotherapy This new Review discusses the role of metabolic pathways in cancer and immune cells in shaping the tumour microenvironment, and how they can be targeted to improve anticancer immune responses

A first-in-class drug being developed by Insmed for the inflammatory lung disease bronchiectasis is expected to become a mega-blockbuster - find out more in our latest news story

RT @adamfeuerstein: Here’s how Insmed $INSM grows to be the next $100 billion biotech. Nektar Therapeutics $NKTR produces a feel-good inves….

Read about progress with therapeutic strategies to target the transcription factor NRF2, a master regulator of proteostasis, metabolism and iron homeostasis, in this review in the June issue.

Generative AI: a generation-defining shift for biopharma regulatory affairs This Comment article discusses how regulatory affairs teams in biopharma companies are beginning to apply generative AI in tasks such as regulatory intelligence management

Ira Mellman, the new president of research at the Parker Institute for Cancer Immunotherapy (@parkici), asks why so many drug developers are retreating from cancer immunotherapies before they have achieved their full potential in our latest interview

For readers interested in GPCR drug discovery, here's a perspective on pharmacological characterization of GPCR modulators and a review on functional dynamics studies revealing new approaches

Our latest research highlight covers a paper in Cell on a biased allosteric modulator of a GPCR, neurotensin receptor 1, that shows antinociceptive properties in rodent pain models without causing side effects or exhibiting addiction potential

RT @diegoadiazg: 🚨 Tumour-agnostic kinase inhibitors are reshaping precision oncology. 🎯 Target the mutation, not the location. Agents lik….

RT @NatureConf: New conference alert 🚨.Cracking The Code, our event on nucleic acid therapies and clinical translation is back and this tim….

The complexities of drug development for inflammatory bowel disease are being discussed at a panel at #BIO2025 - find out more about to navigate these in this Perspective .